First MS Mobility Drug Gets Green Light From NHS England
NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.
How this was made
The 30-second read
Why it matters
The newest fact is the NHSE decision to make fampridine routinely available, including a structured 2-4 week trial period and continuation only for patients showing clear benefit, with an initial eligibility estimate of about 5,000 patients in England.
Market read
A UK coverage approval is a concrete demand-enabler for fampridine, with quantified patient eligibility and a defined trial-and-continue framework that can influence near-term prescribing volumes.
What to watch
The article does not disclose NHS pricing, expected net revenue, or whether the decision changes prescribing behavior versus existing off-label/other symptomatic pathways, which could limit financial upside.
Background
NHS England previously did not routinely recommend fampridine after a 2022 NICE refusal on cost-effectiveness grounds; this year NHSE reviewed drugs not assessed by NICE and concluded routine commissioning for adults with MS walking impairment (EDSS 4-7).
Ticker impact
NHS England approved fampridine (Fampyra) for routine NHS use, a decision that directly expands UK access to Alkermes’ branded therapy.
Moderate positive bias for ALKS on expectations of incremental UK uptake, though likely limited versus global scale.
The article is a regulatory/coverage decision (routine availability) with quantified eligibility (about 5,000 patients in year one), but it does not provide financial terms, pricing, or global commercialization impact.
Market effects
Improves reimbursement/coverage prospects for symptomatic MS therapies in the UK, potentially supporting sentiment toward MS neurology drug developers.
UK NHS commissioning expands near-term patient access in England, with potential read-across to other UK payer decisions.
Could strengthen the commercial narrative for fampridine internationally, but the article is UK-specific and lacks global pricing/volume details.
Counterpoint
Even with routine availability, uptake may be constrained by clinician adoption, patient selection criteria (clear benefit after 2-4 weeks), and budget impact considerations.
Key entities
- regulator/payerNHS England
Announced routine NHS availability of fampridine for adults with MS-related walking impairment.
- drugFampridine (Fampyra)
Potassium channel blocker used to improve walking in adults with MS.
- companyAlkermes
Branded Fampyra is attributed to Alkermes in the article.
- companyMerz Pharma UK
Markets the Fampyra brand in the UK after patent expiry, per the article.
- regulatorNICE
Refused to recommend fampridine in 2022 on cost-effectiveness grounds, referenced as the prior hurdle.
